(5Z,7E,20R)-1α,3β-bis<(tert-butyldimethylsilyl)oxy>-20-formylmethyl-9,10-seco-5,7,10(19)-pregnatriene | 143884-26-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (5Z,7E,20R)-1α,3β-bis<(tert-butyldimethylsilyl)oxy>-20-formylmethyl-9,10-seco-5,7,10(19)-pregnatriene
• 英文别名: (5Z,7E,20R)-1α,3β-bis(tert-butyldimethylsilyloxy)-20-formylmethyl-9,10-seco-5,7,10(19)-pregnatriene；1α,3β-bis-(tert-butyldimethylsilyloxy)-20(R)-formylmethyl-9,10-secopregna-5(Z),7(E),10(19)-triene；1α,3β-bis-(t-butyldimethylsilyloxy)-20(R)-formylmethyl-9,10-secopregna-5(Z),7(E),10(19)-triene；(3R)-3-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(3S,5R)-3,5-bis[[tert-butyl(dimethyl)silyl]oxy]-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]butanal
• CAS: 143884-26-8
• 化学式: C₃₅H₆₂O₃Si₂
• 分子量: 587.046
• InChiKey: GEELQDLYTURMAP-GSFYQCCGSA-N

物化性质

• 沸点：
  579.9±50.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  10.41
• 重原子数：
  40
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (5Z,7E,20R)-1α,3β-bis<(tert-butyldimethylsilyl)oxy>-20-formylmethyl-9,10-seco-5,7,10(19)-pregnatriene 在 四丙基高钌酸铵 咪唑 、 氢氧化钾 、 sodium tetrahydroborate 、 N-甲基吲哚酮 、 甲烷磺酸 、 4 Angstroem MS 、 三正丁基氢锡 、 sodium hydride 、 N,N-二异丙基乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 、 乙醚 、 二氯甲烷 、 氯仿 、 甲苯 为溶剂， 反应 20.42h， 生成 氟骨三醇
  参考文献：
  名称：

  Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D 3

  摘要：

  The activated vitamin D-3 derivative 26,27-F-6-1 alpha,25(OH)(2)D-3 (2a), its three A-ring diastereomers (2b, 2c, 2d), and 5,6-trans isomer (2e) were prepared. Two analogues (2b, 2c) of these isomers were synthesized by a palladium catalyzed coupling reaction using Vinyl bromide 5 and enynes (6a, 6b), which were derived from readily commercially available 2S-(+)-glycidyl p-toluenesulfonate 7, as a common starting material. Competitive vitamin D receptor (VDR) binding affinities of these diastereomers of 2a were evaluated. Interestingly, the stereochemical effects at C-1,3 of 2a were considerably more moderate than those of 1 alpha,25(OH)(2)D-3 (1). In particular, isomerization at the 5,6-double bond of 2a only slightly reduced VDR affinity, whereas 5,6-trans-1 alpha,25(OH)(2)D-3 had a significantly lower binding affinity than 1. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00142-5
• 作为产物：
  描述：

  (5Z,7E)-(1S,3R,20S)-1,3-bis<(tert-butyldimethylsilyl)oxy>-9,10-seco-22,23-dinor-5,7,10(19)-cholatrien-24-ol 在 4-二甲氨基吡啶 、 二异丁基氢化铝 作用下， 以 正己烷 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 7.0h， 生成 (5Z,7E,20R)-1α,3β-bis<(tert-butyldimethylsilyl)oxy>-20-formylmethyl-9,10-seco-5,7,10(19)-pregnatriene
  参考文献：
  名称：

  Practical Synthesis and Evaluation of the Biological Activities of 1α,25-dihydroxyvitamin D₃ Antagonists, 1α,25-dihydroxyvitamin D₃-26,23-lactams. Designed on the Basis of the Helix 12-Folding Inhibition Hypothesis

  摘要：

  A practical synthetic route to novel vitamin D antagonists of DLAM (1 alpha.,25-dihydroxyvitamin D-3-26,23lactam) was developed from vitamin D-2 via the 1,3-dipolar cycloaddition reaction as a key step. Six DLAM derivatives (24 compounds) with a variety of nitrogen substituents and stereochemistries at C23 and C25 were synthesized. Among these new derivatives, (23S,25S)-DLAM isomers bound effectively to VDRs and showed antagonistic activity in the HL-60 cell differentiation inhibition assay. The importance of the substituent on the nitrogen of DLAMs for antagonistic activity was also suggested by computational docking studies.

  DOI：

  10.1021/jm050738x

文献信息

• An Improved Synthesis of 24,24-Difluoro-1.ALPHA.,25-dihydroxyvitamin D3 from Readily Available Vitamin D2.
  作者：Kaori ANDO、Fumiaki KOIKE、Fumihiro KONDO、Hiroaki TAKAYAMA

  DOI：10.1248/cpb.43.189

  日期：——

  An improved synthesis of a highly potent vitamin D3 analog, 24, 24-difluoro-1α, 25-dihydroxyvitamin D3 (1b)has been accomplished via vitamin D2-SO2 adducts. The introduction of fluorine atoms was performed by treating the α-keto ester (11) with diethylaminosulfur trifluoride. The total yield was 12.5% from inexpensive vitamin D2 in 11 steps. This sequence is sufficiently straightforward to be conducted on a gram scale.

  通过维生素D2-SO2加合物，完成了一种高效能维生素D3类似物24, 24-二氟-1α, 25-二羟基维生素D3 (1b) 的改进合成。引入氟原子的过程是通过用二乙胺硫三氟化物处理α-酮酯（11）来实现的。该方法从廉价的维生素D2中在11个步骤中获得了12.5%的总产率。这一序列简单明了，足以在克级规模上进行。
• Synthesis and Biological Evaluation of (23R)- and (23S)-24,24-Difluoro-1.ALPHA.,23,25-trihydroxyvitamin D3.
  作者：Hiroshi IWASAKI、Yoichi MIYAMOTO、Ryuzo HOSOTANI、Yoshio NAKANO、Katsuhiro KONNO、Hiroaki TAKAYAMA

  DOI：10.1248/cpb.46.1932

  日期：——

  The syntheses and biological evaluations of (23R)- and (23S)-24,24-difluoro-1 alpha,23,25-trithydroxyvitamin D3 (3a and 3b), new C-24 fluorinated analogs of 1 alpha,25-dihydroxyvitamin D3, are described. The syntheses of these compounds were achieved in 3 steps from (5Z,7E,20R)-1 alpha,3 beta-bis-[(tert-butyldimethylsilyl)oxy]-20-formylmethyl-9,10-seco- 5,7,10(19) pregnatriene (5) which is derived

  （23R）-和（23S）-24,24-二氟-1α，23,25-三羟甲基维生素D3（3a和3b），1α，25-二羟基维生素D3的新C-24氟化类似物的合成和生物学评估进行说明。从（5Z，7E，20R）-1α，3β-双-[[（叔丁基二甲基甲硅烷基）氧基] -20-甲酰基甲基-9,10-seco-5,7，3分三个步骤完成了这些化合物的合成10（19）孕三烯（5），其衍生自维生素D2。通过改进的Mosher方法确定3a和3b在C-23位置的绝对构型。3a和3b与维生素D受体的相对亲和力分别比1α，25-二羟基维生素D3（1）低10和14倍，对维生素D结合蛋白的亲和力也低130和40倍。3a的HL-60细胞分化活性比1的强6倍
• Vitamin D3 lactam derivative
  申请人：Nagasawa Kazuo

  公开号：US20050182032A1

  公开（公告）日：2005-08-18

  Compounds expressed by the following formula (1) or pharmaceutically permissible solvate thereof which is effective for treating Paget's disease of bone, hypercalcemia or osteoporosis. In the formula, R 1 is a C 2 -C 10 alkyl group, or a C 7 -Cl 5 aralkyl group whose aromatic ring is optionally substituted with a C 1 -C 6 alkyl group, a C 1 -C 6 alkoxyl group, a hydroxyl group, a halogen atom or a trifluoromethyl group; and R 2 is a C 1 -C 10 alkyl group, or a C 7 -C 15 aralkyl group whose aromatic ring is optionally substituted with a C 1 -C 6 alkyl group, a C 1 -C 6 alkoxyl group, a hydroxyl group, a halogen atom or a trifluoromethyl group.

  由以下公式（1）表示的化合物或其药学上可接受的溶剂化合物，对治疗骨骼帕吉特病、高钙血症或骨质疏松症有效。在该公式中，R1是C2-C10烷基基团，或者是一个C7-C15芳基烷基基团，其芳香环可选择地被C1-C6烷基基团、C1-C6甲氧基基团、羟基、卤原子或三氟甲基取代；而R2是一个C1-C10烷基基团，或者是一个C7-C15芳基烷基基团，其芳香环可选择地被C1-C6烷基基团、C1-C6甲氧基基团、羟基、卤原子或三氟甲基取代。
• VITAMIN D3 LACTONE DERIVATIVE
  申请人：Teijin Pharma Limited

  公开号：EP1589009B1

  公开（公告）日：2014-10-08
• EP1477483
  申请人：——

  公开号：——

  公开（公告）日：——